CN101909630A - 预防和治疗肿瘤的方法和化合物 - Google Patents

预防和治疗肿瘤的方法和化合物 Download PDF

Info

Publication number
CN101909630A
CN101909630A CN2008801234004A CN200880123400A CN101909630A CN 101909630 A CN101909630 A CN 101909630A CN 2008801234004 A CN2008801234004 A CN 2008801234004A CN 200880123400 A CN200880123400 A CN 200880123400A CN 101909630 A CN101909630 A CN 101909630A
Authority
CN
China
Prior art keywords
histone
cell
dact
tumor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801234004A
Other languages
English (en)
Chinese (zh)
Inventor
于强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of CN101909630A publication Critical patent/CN101909630A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2008801234004A 2007-11-02 2008-11-03 预防和治疗肿瘤的方法和化合物 Pending CN101909630A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98483507P 2007-11-02 2007-11-02
US60/984,835 2007-11-02
US5948208P 2008-06-06 2008-06-06
US61/059,482 2008-06-06
PCT/SG2008/000420 WO2009058102A1 (en) 2007-11-02 2008-11-03 Methods and compounds for preventing and treating a tumour

Publications (1)

Publication Number Publication Date
CN101909630A true CN101909630A (zh) 2010-12-08

Family

ID=40591309

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801234004A Pending CN101909630A (zh) 2007-11-02 2008-11-03 预防和治疗肿瘤的方法和化合物

Country Status (6)

Country Link
US (2) US8969313B2 (https=)
EP (1) EP2217240A4 (https=)
JP (1) JP2011504462A (https=)
CN (1) CN101909630A (https=)
SG (1) SG185942A1 (https=)
WO (1) WO2009058102A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103627785A (zh) * 2011-12-16 2014-03-12 香港中文大学 胃癌的生物标志物dact1
CN105567797A (zh) * 2014-11-11 2016-05-11 香港中文大学深圳研究院 检测DACT2基因启动子区CpG岛甲基化的PCR引物、方法和试剂盒
CN108026578A (zh) * 2015-09-25 2018-05-11 艾皮恩蒂斯有限公司 Lrp5作为用于鉴定免疫细胞特别是b细胞的表观遗传标志物
CN110408688A (zh) * 2019-05-22 2019-11-05 中山大学附属第一医院 Dact1基因在制备房颤诊断和治疗产品中的应用
CN111802326A (zh) * 2020-07-09 2020-10-23 中山大学附属口腔医院 一种Kras突变相关口腔黏膜恶变动物模型的构建方法
CN114561466A (zh) * 2022-01-25 2022-05-31 中山大学附属第一医院 Fto在诊治骨肉瘤中的应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189097A1 (en) * 2009-11-09 2011-08-04 Dritan Agalliu Use of WNT inhibitor to inhibit angiogenesis in the CNS
EP2569625A4 (en) * 2010-05-11 2013-12-04 Ann And Robert H Lurie Children S Hospital Of Chicago METHOD FOR DETECTING AND PROFILING THE PROGRESS OF THE RISK OF A NEURODEEGENERATIVE DISEASE
EP2666020A1 (en) * 2011-01-18 2013-11-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for amplification and detection of prions
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2017019721A2 (en) * 2015-07-28 2017-02-02 Constellation Pharmaceuticals, Inc. Combination therapies for modulation of histone methyl modifying enzymes
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
FR3042202B1 (fr) * 2015-10-13 2020-02-07 Institut National De La Recherche Agronomique Procede de criblage de composes a effet anti-inflammatoire base sur la proteine dact3 et nouvelles strategies therapeutiques
US10765471B2 (en) 2016-04-15 2020-09-08 Bolder Surgical, Llc Electrosurgical sealer and divider
JP7239468B2 (ja) * 2016-10-06 2023-03-14 ザ・ジョンズ・ホプキンス・ユニバーシティ ラージスケールエピゲノムのリプログラミングは、膵癌進行の進展中の同化グルコース代謝を遠位転移に結びつける
US20180139464A1 (en) * 2016-11-17 2018-05-17 Mediatek Inc. Decoding system for tile-based videos
CN114994323B (zh) * 2021-02-20 2024-12-24 中国医学科学院基础医学研究所 IgG Fc N-糖肽作为确定或辅助肺癌治疗方案选择的标志物的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57102889A (en) 1980-12-19 1982-06-26 Toyo Jozo Co Ltd 2'-(r)-substituted-2'-deoxyneplanocin a derivative
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
JPH02215781A (ja) 1989-02-14 1990-08-28 Toyo Jozo Co Ltd ６’―デオキシ―６’―ハロゲノネプラノシンａおよびその製造法
DE69105495T2 (de) 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
JP2002507404A (ja) 1998-03-27 2002-03-12 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド−抗ＨＥＲ−２抗体相乗作用
SE517975C2 (sv) 2000-05-30 2002-08-13 Power Ab C Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion
KR20090089922A (ko) * 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
US20050191618A1 (en) 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
US20050245559A1 (en) 2004-01-23 2005-11-03 Koul Hari K Treatment and prevention of prostate cancer
WO2005105136A1 (en) 2004-04-27 2005-11-10 University Of South Florida Nanogene therapy for cell proliferation disorders
ATE511859T1 (de) 2004-07-20 2011-06-15 Schering Corp Apoptoseinduktion in toll-artige rezeptoren exprimierenden tumorzellen
JP2009514891A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためのｓａｈａ及びエルロチニブを用いる方法
AU2006339445A1 (en) 2006-03-02 2007-09-07 Agency For Science, Technology And Research Methods for cancer therapy and stem cell modulation
EP2144606A2 (en) 2007-04-05 2010-01-20 Max-Delbrück-Centrum Für Molekulare Medizin Remedy for the treatment of cardio-vascular diseases or disorders

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103627785A (zh) * 2011-12-16 2014-03-12 香港中文大学 胃癌的生物标志物dact1
US9090944B2 (en) 2011-12-16 2015-07-28 The Chinese University Of Hong Kong Biomarker DACT1 for gastric cancer
CN103627785B (zh) * 2011-12-16 2019-04-23 香港中文大学 胃癌的生物标志物dact1
CN105567797A (zh) * 2014-11-11 2016-05-11 香港中文大学深圳研究院 检测DACT2基因启动子区CpG岛甲基化的PCR引物、方法和试剂盒
CN108026578A (zh) * 2015-09-25 2018-05-11 艾皮恩蒂斯有限公司 Lrp5作为用于鉴定免疫细胞特别是b细胞的表观遗传标志物
CN110408688A (zh) * 2019-05-22 2019-11-05 中山大学附属第一医院 Dact1基因在制备房颤诊断和治疗产品中的应用
CN111802326A (zh) * 2020-07-09 2020-10-23 中山大学附属口腔医院 一种Kras突变相关口腔黏膜恶变动物模型的构建方法
CN114561466A (zh) * 2022-01-25 2022-05-31 中山大学附属第一医院 Fto在诊治骨肉瘤中的应用
CN114561466B (zh) * 2022-01-25 2023-06-13 中山大学附属第一医院 Fto在诊治骨肉瘤中的应用

Also Published As

Publication number Publication date
US8969313B2 (en) 2015-03-03
US20160015693A1 (en) 2016-01-21
EP2217240A1 (en) 2010-08-18
WO2009058102A1 (en) 2009-05-07
JP2011504462A (ja) 2011-02-10
EP2217240A4 (en) 2012-09-12
US20110053882A1 (en) 2011-03-03
SG185942A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
CN101909630A (zh) 预防和治疗肿瘤的方法和化合物
Zhao et al. Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer
Wang et al. Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis
KR102373074B1 (ko) 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
Chen et al. Deacetylation of β-catenin by SIRT1 regulates self-renewal and oncogenesis of liver cancer stem cells
Corvalan et al. Methylation of histone 4’s lysine 20: a critical analysis of the state of the field
JP2022116353A (ja) Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法
EP3052655B1 (en) Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed
JP2015529665A (ja) Ｍｔｈ１阻害剤としてのアミノヘテロアリール化合物
Luo et al. Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability
Liekens et al. The thymidine phosphorylase inhibitor 5′-O-tritylinosine (KIN59) is an antiangiogenic multitarget fibroblast growth factor-2 antagonist
Lou et al. Insight into the physiological and pathological roles of USP44, a potential tumor target
JP2021167301A (ja) Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
WO2013166366A1 (en) Cul4b as predictive biomarker for cancer treatment
Kim et al. USP11 modulates mitotic progression and senescence by regulating the p53-p21 axis through MDM2 deubiquitination
JP2014506871A (ja) 虚血／再灌流傷害を治療する方法
US20250146080A1 (en) Methods for overcoming tazemetostat-resistance in cancer patients
Nandi Cellular and metabolic reprogramming in breast Cancer and its therapeutic implications
Elkabets et al. Pharmacological activation of SIRT6 suppresses progression of head and neck and esophagus squamous cell carcinoma by modulation of cellular metabolism and protein translation
Wang et al. Williams syndrome transcription factor is a target of pro-oncogenic Ser158 phosphorylation mediated by Ras-MAPK pathway in human breast cancer
Yu Crosstalk of Myotubularin-related protein 7 with RAS/WNT Driver Pathways in Colorectal Cancer
Kelleher et al. Wnt signaling and synovial sarcoma
Gritsina Atypical Chemokine Receptor CXCR7 Signaling and Prostate Cancer Progression
US20230174537A1 (en) Isoform-Specific Aldehyde Dehydrogenase Inhibitors
Sanchez Novel Strategies for Combatting Acquired Resistance to Combined BRAF and MEK Inhibition in Mutant BRAF Melanomas

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101208